Uncategorized
Visual acuity remains unchanged after switch to aflibercept treatment
A switch to aflibercept treatment in patients with neovascular age-related macular degeneration resulted in a significant decrease in the number of injections, central retinal thickness and retinal pigment epithelial detachment volume, but visual acuity remained unchanged, according to a study.The retrospective study included 73 eyes of 65 patients with neovascular AMD who switched to Eylea (aflibercept, Regeneron) because of persistent macular fluid after treatment with intravitreal Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech). Patients received bevacizumab or ranibizumab for at least 1 year, with re-treatment at least every 6 weeks, (Read more...)